Summary

The molecular diagnostics industry is entering a transformative phase, underpinned by its expanding role in precision medicine, infectious disease detection, and genetic testing. As healthcare systems worldwide embrace more accurate, efficient, and timely diagnostic solutions, molecular diagnostics is gaining prominence as a cornerstone of modern medical practice. This technology enables the identification of diseases at the genetic level, allowing for early intervention and targeted treatment strategies.

Market Outlook

The global molecular diagnostics market is expected to surge from US$24.97 billion in 2025 to US$40.32 billion by 2032, expanding at a steady CAGR of 7.08%. This growth is driven by rising awareness of molecular-level disease detection, technological innovations, and increasing prevalence of chronic and infectious diseases. Molecular diagnostics, once considered a specialized tool, is now being rapidly adopted in mainstream healthcare due to its efficiency and accuracy in disease detection.

Market Drivers

Expanding Use of Companion Diagnostics

Companion diagnostics, a vital segment within molecular diagnostics, is becoming increasingly essential in personalized medicine. With targeted therapies gaining momentum in oncology and other therapeutic fields, companion diagnostic tests are necessary to identify biomarkers that predict patient response. Technologies such as next-generation sequencing (NGS) support multi-gene analysis, allowing for detailed patient profiling and optimized therapeutic outcomes.

Rapid Adoption of Liquid Biopsy Technologies

Liquid biopsy is emerging as a game-changer in the molecular diagnostics space. These non-invasive tests allow for real-time monitoring of tumor dynamics and treatment efficacy through the analysis of blood samples. This innovation is particularly useful in detecting cancers where traditional biopsies are challenging. Research into glioblastoma (GB) and the identification of biomarkers like MGMT methylation via liquid biopsy is setting the stage for more precise and dynamic clinical interventions.

Business Opportunities

Supportive Government Policies and Evolving Regulations

Governments and regulatory agencies around the world are actively supporting the growth of molecular diagnostics. The COVID-19 pandemic highlighted the importance of technologies like RT-PCR and genome sequencing, leading to widespread infrastructure development and training across healthcare institutions.

Differing regulatory environments, such as those between the US and Europe, offer molecular diagnostics companies opportunities to tailor their strategies for regional success. Firms can leverage FDA approvals for US market credibility, while collaborating with healthcare systems in the EU to enhance in-house testing capabilities.

Challenges

High Cost of Instruments and Reagents

One of the primary challenges facing the molecular diagnostics market is the high upfront cost associated with advanced instruments and reagents. Small and mid-sized laboratories often struggle to invest in state-of-the-art diagnostic equipment, which can limit technology adoption in cost-sensitive markets.

Additionally, recurring expenses for consumables such as PCR kits, enzymes, and reagents significantly increase operational costs. Maintenance and calibration of diagnostic devices add to the total cost of ownership, creating barriers for widespread implementation in resource-limited settings.

Workforce and Training Limitations

Operating molecular diagnostics equipment demands skilled personnel proficient in molecular biology, genetics, and biochemistry. The need for highly trained professionals poses another constraint, especially in regions where access to specialized education and training is limited. Smaller healthcare facilities may find it difficult to allocate budgets for extensive training programs, thereby slowing the pace of adoption.

Regional Analysis

North America

North America remains the largest and most mature market for molecular diagnostics, driven by early adoption of technological innovations and a robust healthcare infrastructure. The region continues to experience high demand for early disease detection, particularly in cancer, cardiovascular conditions, and genetic disorders. The strong presence of key industry players and ongoing investment in R&D further solidify North America’s leadership in this space.

Asia Pacific

Asia Pacific is witnessing a rapid rise in demand for molecular diagnostic tools due to a growing burden of infectious and chronic diseases, large population base, and increasing healthcare expenditure. The demand for portable and point-of-care diagnostic solutions is particularly strong in rural and underserved regions. Companies offering cost-effective and easy-to-use diagnostic tools are well-positioned to tap into this high-growth market.

Key Players

Several global players are actively shaping the molecular diagnostics Analysis through continuous innovation and strategic collaborations. Key companies include:

• Roche Diagnostics

• Thermo Fisher Scientific Inc.

• Abbott Laboratories

• Siemens Healthineers AG

• Becton, Dickinson and Company

• Illumina, Inc.

• Qiagen N.V.

• Hologic Inc.

• Agilent Technologies, Inc.

• bioMérieux

• Bio-Rad Laboratories Inc.

• Seegene, Inc.

• DiaSorin S.p.A

• Grifols, S.A.

• QuidelOrtho Corporation

• Merck KGaA

• RapidBio

• Danaher Corporation

These companies are focusing on product innovation, expanding their diagnostic portfolios, and entering new geographic markets to stay ahead in a competitive environment.

Recent Developments

• In July 2023, Illumina Inc. and Pillar Biosciences Inc. announced a strategic partnership to expand the global reach of oncology assays, reinforcing their commitment to precision medicine.

• In October 2023, Roche received FDA approval for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify metastatic breast cancer patients with low HER2 expression, improving targeted therapy options.

Analyst Perspective

The molecular diagnostics market has significantly evolved since the onset of the COVID-19 pandemic, which accelerated investment in diagnostic infrastructure and heightened public and institutional awareness. Molecular diagnostics has transcended its traditional applications in infectious disease to play a crucial role in genomics, pharmacogenomics, and biomarker discovery.

The integration of molecular diagnostics into routine healthcare is being driven by the need for accurate, real-time disease monitoring and personalized therapy. With continued advancements in technologies like NGS, digital PCR, and liquid biopsy, the industry is poised for sustained growth and greater impact across diverse healthcare sectors.

Market Segmentation

By Product Type

• Instruments

o Polymerase Chain Reaction (PCR) Systems

o Hybridization (In-Situ Hybridization & FISH) Systems

o DNA Sequencing and Next-Generation Sequencing Platforms

o Microarrays

• Reagents

o Antibodies

o DNA Template

o DNA Polymerase

o Oligonucleotide Primers

o Deoxyribonucleotide Triphosphate (dNTPs)

o Buffer

• Assay Kits

• Consumables

By Disease Area

• Infectious Disease

• Diabetes

• Cardiology

• Oncology

• Nephrology

• Autoimmune Disease

• Dermatology

• Wound Care

• Others

By End Use

• Hospitals & Clinics

• Diagnostics Laboratories

• Academic and Research Institutes

• Biopharmaceutical Companies

By Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Molecular Diagnostics Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Molecular Diagnostics Market Outlook, 2019-2032
3.1. Global Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
3.1.1. Key Highlights
3.1.1.1. Instruments
3.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
3.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
3.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
3.1.1.1.4. Microarrays
3.1.1.2. Reagent
3.1.1.2.1. Antibodies
3.1.1.2.2. DNA Template
3.1.1.2.3. DNA Polymerase
3.1.1.2.4. Oligonucleotide Primers
3.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
3.1.1.2.6. Buffer
3.1.1.3. Assay Kits
3.1.1.4. Consumables
3.2. Global Molecular Diagnostics Market Outlook, by Disease Area, Value (US$ Bn), 2019-2032
3.2.1. Key Highlights
3.2.1.1. Infectious Disease
3.2.1.2. Diabetes
3.2.1.3. Cardiology
3.2.1.4. Oncology
3.2.1.5. Nephrology
3.2.1.6. Autoimmune Disease
3.2.1.7. Dermatology
3.2.1.8. Wound Care
3.2.1.9. Others
3.3. Global Molecular Diagnostics Market Outlook, by End-use, Value (US$ Bn), 2019-2032
3.3.1. Key Highlights
3.3.1.1. Hospitals & Clinics
3.3.1.2. Diagnostics Laboratories
3.3.1.3. Academic and Research Institutes
3.3.1.4. Biopharmaceutical Companies
3.4. Global Molecular Diagnostics Market Outlook, by Region, Value (US$ Bn), 2019-2032
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Molecular Diagnostics Market Outlook, 2019-2032
4.1. North America Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
4.1.1. Key Highlights
4.1.1.1. Instruments
4.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
4.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
4.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
4.1.1.1.4. Microarrays
4.1.1.2. Reagent
4.1.1.2.1. Antibodies
4.1.1.2.2. DNA Template
4.1.1.2.3. DNA Polymerase
4.1.1.2.4. Oligonucleotide Primers
4.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
4.1.1.2.6. Buffer
4.1.1.3. Assay Kits
4.1.1.4. Consumables
4.2. North America Molecular Diagnostics Market Outlook, by Disease Area, Value (US$ Bn), 2019-2032
4.2.1. Key Highlights
4.2.1.1. Infectious Disease
4.2.1.2. Diabetes
4.2.1.3. Cardiology
4.2.1.4. Oncology
4.2.1.5. Nephrology
4.2.1.6. Autoimmune Disease
4.2.1.7. Dermatology
4.2.1.8. Wound Care
4.2.1.9. Others
4.3. North America Molecular Diagnostics Market Outlook, by End-use, Value (US$ Bn), 2019-2032
4.3.1. Key Highlights
4.3.1.1. Hospitals & Clinics
4.3.1.2. Diagnostics Laboratories
4.3.1.3. Academic and Research Institutes
4.3.1.4. Biopharmaceutical Companies
4.3.2. Attractiveness Analysis
4.4. North America Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
4.4.1. Key Highlights
4.4.1.1. U.S. Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
4.4.1.2. U.S. Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
4.4.1.3. U.S. Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
4.4.1.4. Canada Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
4.4.1.5. Canada Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
4.4.1.6. Canada Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
5. Europe Molecular Diagnostics Market Outlook, 2019-2032
5.1. Europe Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
5.1.1. Key Highlights
5.1.1.1. Instruments
5.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
5.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
5.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
5.1.1.1.4. Microarrays
5.1.1.2. Reagent
5.1.1.2.1. Antibodies
5.1.1.2.2. DNA Template
5.1.1.2.3. DNA Polymerase
5.1.1.2.4. Oligonucleotide Primers
5.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
5.1.1.2.6. Buffer
5.1.1.3. Assay Kits
5.1.1.4. Consumables
5.2. Europe Molecular Diagnostics Market Outlook, by Disease Area, Value (US$ Bn), 2019-2032
5.2.1. Key Highlights
5.2.1.1. Infectious Disease
5.2.1.2. Diabetes
5.2.1.3. Cardiology
5.2.1.4. Oncology
5.2.1.5. Nephrology
5.2.1.6. Autoimmune Disease
5.2.1.7. Dermatology
5.2.1.8. Wound Care
5.2.1.9. Others
5.3. Europe Molecular Diagnostics Market Outlook, by End-use, Value (US$ Bn), 2019-2032
5.3.1. Key Highlights
5.3.1.1. Hospitals & Clinics
5.3.1.2. Diagnostics Laboratories
5.3.1.3. Academic and Research Institutes
5.3.1.4. Biopharmaceutical Companies
5.3.2. Attractiveness Analysis
5.4. Europe Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
5.4.1. Key Highlights
5.4.1.1. Germany Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
5.4.1.2. Germany Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
5.4.1.3. Germany Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
5.4.1.4. U.K. Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
5.4.1.5. U.K. Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
5.4.1.6. U.K. Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
5.4.1.7. France Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
5.4.1.8. France Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
5.4.1.9. France Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
5.4.1.10. Italy Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
5.4.1.11. Italy Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
5.4.1.12. Italy Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
5.4.1.13. Turkey Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
5.4.1.14. Turkey Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
5.4.1.15. Turkey Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
5.4.1.16. Russia Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
5.4.1.17. Russia Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
5.4.1.18. Russia Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
5.4.1.19. Rest of Europe Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
5.4.1.20. Rest of Europe Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
5.4.1.21. Rest of Europe Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
6. Asia Pacific Molecular Diagnostics Market Outlook, 2019-2032
6.1. Asia Pacific Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
6.1.1. Key Highlights
6.1.1.1. Instruments
6.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
6.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
6.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
6.1.1.1.4. Microarrays
6.1.1.2. Reagent
6.1.1.2.1. Antibodies
6.1.1.2.2. DNA Template
6.1.1.2.3. DNA Polymerase
6.1.1.2.4. Oligonucleotide Primers
6.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
6.1.1.2.6. Buffer
6.1.1.3. Assay Kits
6.1.1.4. Consumables
6.2. Asia Pacific Molecular Diagnostics Market Outlook, by Disease Area, Value (US$ Bn), 2019-2032
6.2.1. Key Highlights
6.2.1.1. Infectious Disease
6.2.1.2. Diabetes
6.2.1.3. Cardiology
6.2.1.4. Oncology
6.2.1.5. Nephrology
6.2.1.6. Autoimmune Disease
6.2.1.7. Dermatology
6.2.1.8. Wound Care
6.2.1.9. Others
6.3. Asia Pacific Molecular Diagnostics Market Outlook, by End-use, Value (US$ Bn), 2019-2032
6.3.1. Key Highlights
6.3.1.1. Hospitals & Clinics
6.3.1.2. Diagnostics Laboratories
6.3.1.3. Academic and Research Institutes
6.3.1.4. Biopharmaceutical Companies
6.3.2. Attractiveness Analysis
6.4. Asia Pacific Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
6.4.1. Key Highlights
6.4.1.1. China Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
6.4.1.2. China Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
6.4.1.3. China Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
6.4.1.4. Japan Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
6.4.1.5. Japan Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
6.4.1.6. Japan Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
6.4.1.7. South Korea Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
6.4.1.8. South Korea Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
6.4.1.9. South Korea Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
6.4.1.10. India Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
6.4.1.11. India Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
6.4.1.12. India Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
6.4.1.13. Southeast Asia Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
6.4.1.14. Southeast Asia Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
6.4.1.15. Southeast Asia Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
6.4.1.16. Rest of Asia Pacific Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
6.4.1.17.
6.4.1.18. Rest of Asia Pacific Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
6.4.1.19. Rest of Asia Pacific Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
7. Latin America Molecular Diagnostics Market Outlook, 2019-2032
7.1. Latin America Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
7.1.1. Key Highlights
7.1.1.1. Instruments
7.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
7.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
7.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
7.1.1.1.4. Microarrays
7.1.1.2. Reagent
7.1.1.2.1. Antibodies
7.1.1.2.2. DNA Template
7.1.1.2.3. DNA Polymerase
7.1.1.2.4. Oligonucleotide Primers
7.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
7.1.1.2.6. Buffer
7.1.1.3. Assay Kits
7.1.1.4. Consumables
7.2. Latin America Molecular Diagnostics Market Outlook, by Disease Area, Value (US$ Bn), 2019-2032
7.2.1. Key Highlights
7.2.1.1. Infectious Disease
7.2.1.2. Diabetes
7.2.1.3. Cardiology
7.2.1.4. Oncology
7.2.1.5. Nephrology
7.2.1.6. Autoimmune Disease
7.2.1.7. Dermatology
7.2.1.8. Wound Care
7.2.1.9. Others
7.3. Latin America Molecular Diagnostics Market Outlook, by End-use, Value (US$ Bn), 2019-2032
7.3.1. Key Highlights
7.3.1.1. Hospitals & Clinics
7.3.1.2. Diagnostics Laboratories
7.3.1.3. Academic and Research Institutes
7.3.1.4. Biopharmaceutical Companies
7.3.2. Attractiveness Analysis
7.4. Latin America Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
7.4.1. Key Highlights
7.4.1.1. Brazil Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
7.4.1.2. Brazil Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
7.4.1.3. Brazil Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
7.4.1.4. Mexico Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
7.4.1.5. Mexico Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
7.4.1.6. Mexico Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
7.4.1.7. Argentina Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
7.4.1.8. Argentina Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
7.4.1.9. Argentina Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
7.4.1.10. Rest of Latin America Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
7.4.1.11. Rest of Latin America Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
7.4.1.12. Rest of Latin America Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
8. Middle East & Africa Molecular Diagnostics Market Outlook, 2019-2032
8.1. Middle East & Africa Molecular Diagnostics Market Outlook, by Product Type, Value (US$ Bn), 2019-2032
8.1.1. Key Highlights
8.1.1.1. Instruments
8.1.1.1.1. Polymerase Chain Reaction (PCR) Systems
8.1.1.1.2. Hybridization (In-Situ Hybridization & Fish) Systems
8.1.1.1.3. DNA Sequencing and Next-Generation Sequencing Platforms
8.1.1.1.4. Microarrays
8.1.1.2. Reagent
8.1.1.2.1. Antibodies
8.1.1.2.2. DNA Template
8.1.1.2.3. DNA Polymerase
8.1.1.2.4. Oligonucleotide Primers
8.1.1.2.5. Deoxyribonucleotide Triphosphate (dNTPs)
8.1.1.2.6. Buffer
8.1.1.3. Assay Kits
8.1.1.4. Consumables
8.2. Middle East & Africa Molecular Diagnostics Market Outlook, by Disease Area, Value (US$ Bn), 2019-2032
8.2.1. Key Highlights
8.2.1.1. Infectious Disease
8.2.1.2. Diabetes
8.2.1.3. Cardiology
8.2.1.4. Oncology
8.2.1.5. Nephrology
8.2.1.6. Autoimmune Disease
8.2.1.7. Dermatology
8.2.1.8. Wound Care
8.2.1.9. Others
8.3. Middle East & Africa Molecular Diagnostics Market Outlook, by End-use, Value (US$ Bn), 2019-2032
8.3.1. Key Highlights
8.3.1.1. Hospitals & Clinics
8.3.1.2. Diagnostics Laboratories
8.3.1.3. Academic and Research Institutes
8.3.1.4. Biopharmaceutical Companies
8.3.2. Attractiveness Analysis
8.4. Middle East & Africa Molecular Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032
8.4.1. Key Highlights
8.4.1.1. GCC Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
8.4.1.2. GCC Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
8.4.1.3. GCC Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
8.4.1.4. South Africa Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
8.4.1.5. South Africa Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
8.4.1.6. South Africa Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
8.4.1.7. Egypt Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
8.4.1.8. Egypt Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
8.4.1.9. Egypt Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
8.4.1.10. Nigeria Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
8.4.1.11. Nigeria Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
8.4.1.12. Nigeria Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
8.4.1.13. Rest of Middle East & Africa Molecular Diagnostics Market by Product Type, Value (US$ Bn), 2019-2032
8.4.1.14. Rest of Middle East & Africa Molecular Diagnostics Market by Disease Area, Value (US$ Bn), 2019-2032
8.4.1.15. Rest of Middle East & Africa Molecular Diagnostics Market by End-use, Value (US$ Bn), 2019-2032
9. Competitive Landscape
9.1. By Product Type vs by Disease Area Heatmap
9.2. Company Market Share Analysis, 2025
9.3. Competitive Dashboard
9.4. Company Profiles
9.4.1. Becton, Dickinson and Company
9.4.1.1. Company Overview
9.4.1.2. Product Portfolio
9.4.1.3. Financial Overview
9.4.1.4. Business Strategies and Development
9.4.2. Bio-Rad Laboratories In
9.4.2.1. Company Overview
9.4.2.2. Product Portfolio
9.4.2.3. Financial Overview
9.4.2.4. Business Strategies and Development
9.4.3. Merck KgaA
9.4.3.1. Company Overview
9.4.3.2. Product Portfolio
9.4.3.3. Financial Overview
9.4.3.4. Business Strategies and Development
9.4.4. Thermo Fisher Scientific Inc
9.4.4.1. Company Overview
9.4.4.2. Product Portfolio
9.4.4.3. Financial Overview
9.4.4.4. Business Strategies and Development
9.4.5. Agilent Technologies, Inc.
9.4.5.1. Company Overview
9.4.5.2. Product Portfolio
9.4.5.3. Financial Overview
9.4.5.4. Business Strategies and Development
9.4.6. F. Hoffman - La Roche Ltd.
9.4.6.1. Company Overview
9.4.6.2. Product Portfolio
9.4.6.3. Financial Overview
9.4.6.4. Business Strategies and Development
9.4.7. Illumina, Inc.
9.4.7.1. Company Overview
9.4.7.2. Product Portfolio
9.4.7.3. Financial Overview
9.4.7.4. Business Strategies and Development
9.4.8. Qiagen N.V.
9.4.8.1. Company Overview
9.4.8.2. Product Portfolio
9.4.8.3. Financial Overview
9.4.8.4. Business Strategies and Development
9.4.9. Hologic Inc.
9.4.9.1. Company Overview
9.4.9.2. Product Portfolio
9.4.9.3. Financial Overview
9.4.9.4. Business Strategies and Development
9.4.10. Siemens Healthineers AG
9.4.10.1. Company Overview
9.4.10.2. Product Portfolio
9.4.10.3. Financial Overview
9.4.10.4. Business Strategies and Development
9.4.11. Seegene, Inc.
9.4.11.1. Company Overview
9.4.11.2. Product Portfolio
9.4.11.3. Financial Overview
9.4.11.4. Business Strategies and Development
9.4.12. DiaSorin S.p.A
9.4.12.1. Company Overview
9.4.12.2. Product Portfolio
9.4.12.3. Financial Overview
9.4.12.4. Business Strategies and Development
9.4.13. Grifols, S.A.
9.4.13.1. Company Overview
9.4.13.2. Product Portfolio
9.4.13.3. Financial Overview
9.4.13.4. Business Strategies and Development
9.4.14. bioMérieux
9.4.14.1. Company Overview
9.4.14.2. Product Portfolio
9.4.14.3. Financial Overview
9.4.14.4. Business Strategies and Development
9.4.15. QuidelOrtho Corporation
9.4.15.1. Company Overview
9.4.15.2. Product Portfolio
9.4.15.3. Financial Overview
9.4.15.4. Business Strategies and Development
9.4.16. RapidBio
9.4.16.1. Company Overview
9.4.16.2. Product Portfolio
9.4.16.3. Financial Overview
9.4.16.4. Business Strategies and Development
9.4.17. Abbott Laboratories
9.4.17.1. Company Overview
9.4.17.2. Product Portfolio
9.4.17.3. Financial Overview
9.4.17.4. Business Strategies and Development
9.4.18. Danaher Corporation
9.4.18.1. Company Overview
9.4.18.2. Product Portfolio
9.4.18.3. Financial Overview
9.4.18.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations